Definitive Contract 75N93022C00061
Award Date
9/22/22
Potential Completion Date
9/30/26
Potential Value
$26M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Revagenix Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Mateo, CA 94401, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
30
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $7,621,277 cost-plus-fixed-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Microbiotix, Inc., a biopharmaceutical company located in Worcester, Massachusetts. The contract is for the development of phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement from NIAID...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
This federal contract award to Microbiotix, Inc., a clinical-stage biopharmaceutical company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a Broad Agency Announcement (BAA). The $14,195,727 cost-plus-fixed-fee contract supports the development of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (also doing business as Forge Therapeutics) to develop an LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This work will be performed in San Diego, California over 14 months. There is no set-aside designation associated with this contract....
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Pharmacology Discovery Services Taiwan, Ltd., a for-profit Taiwanese company that provides preclinical disease modeling services. The $506,429.00 delivery order is for the development and testing of murine (mouse) models of lung infections caused by antibiotic-resistant Pseudomonas aeruginosa bacteria, to support...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside designation....
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to The Global Alliance For TB Drug Development Inc., a non-profit organization. The $9,851,406.00 cost-no-fee contract is for the development of a novel modulator targeting proteostasis for the treatment of M. tuberculosis, with a completion date of April 30, 2028. The contract was awarded under NIAID's Broad...